Endocrine Response Articles & Analysis

3 news found

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX Test

(NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial were published in The New England Journal of Medicine. ...

Dec. 2, 2021

ByExact Sciences UK, Ltd.

New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer

This guideline update follows the recent presentation of initial results from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial, led by the independent SWOG Cancer Research Network and sponsored by the National Cancer Institute. ...

Mar. 25, 2021

ByExact Sciences UK, Ltd.

RxPONDER Study Results Demonstrate that the Oncotype DX Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

(NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial successfully defined the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score results of 0 to 25. ...

Dec. 9, 2020

ByExact Sciences UK, Ltd.

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you